Bayer Urges 9th Circ. Not To Revive Tevra Flea, Tick Meds Suit

By Editorial Team

Bayer is urging the Ninth Circuit not to grant a new trial over claims that it locked up the market for pet flea and tick treatment, saying the only evidence that rival Tevra showed a jury at trial was “highly dubious.”

The case involves allegations that Bayer engaged in anti-competitive practices to maintain a monopoly over the flea and tick medication market, specifically targeting Tevra, a competitor in the industry.

Bayer’s legal team, represented by Arnold & Porter, argued that the evidence presented by Tevra during the trial was unreliable and should not be grounds for a new trial. Polsinelli PC is representing Tevra in this legal battle.

The lawsuit, which is currently before the U.S. Court of Appeals for the Ninth Circuit, has attracted significant attention within the life sciences and retail sectors due to its potential implications for competition in the pet care industry.

Judge Beth L. Freeman is presiding over the case, and her decision on whether to grant a new trial could have far-reaching consequences for both Bayer and Tevra, as well as the broader market for flea and tick medications.

Legal experts are closely monitoring the developments in this case, as it could set a precedent for how antitrust and competition laws are applied in the context of the pet care industry.